Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)

Avalo Therapeutics (AVTX) reported Current Deferred Revenue of $111000.0 for Q1 2023, up 26.14% quarter-over-quarter from $88000.0 in Q4 2022.

Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023) Analysis & Trends

Avalo Therapeutics has reported Current Deferred Revenue for 2 years, with the latest figure at $111000.0 in Q1 2023.

For the quarter ending Q1 2023, Current Deferred Revenue changed N/A year-over-year to $111000.0; the trailing twelve-month figure through Mar 2023 stood at $111000.0 (changed N/A YoY), and the FY2022 full-year result was $88000.0, changed N/A from the prior year.
Current Deferred Revenue for Q1 2023 stood at $111000.0, up from $88000.0 in the prior quarter.
The five-year high for Current Deferred Revenue was $400000.0 in Q3 2022, with the low at $88000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Avalo Therapeutics	295.77 Mn	295.77 Mn	-

Download Data